12,841 resources
Start Prev Rows 4400 - 4600 Next
| Package | Version | Identity | Name/Title | Status | FMM | WG | Date | Auth | Source(s) |
|---|---|---|---|---|---|---|---|---|---|
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.6 | Food Insecurity Interventions SNOMED CT | active | 2024-12 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.61 | Elder Abuse Diagnoses ICD10CM | active | 2023-08 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.62 | Elder Abuse Diagnoses SNOMED CT | active | 2024-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.63 | Elder Abuse Diagnoses | active | 2022-01 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.64 | Elder Abuse Goals SNOMED CT | active | 2024-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.66 | Elder Abuse Interventions SNOMED CT | active | 2024-12 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.69 | Unemployment Goals SNOMED CT | active | 2024-12 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.71 | Social Determinants of Health Goals | active | 2024-12 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.72 | Stress Diagnoses SNOMED CT | active | 2024-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.73 | Stress Interventions SNOMED CT | active | 2024-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.74 | Stress Diagnoses ICD10CM | active | 2024-06 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.75 | Stress Diagnoses | active | 2024-06 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.76 | Veteran Status Diagnoses SNOMED CT | active | 2024-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.77 | Veteran Status Diagnoses ICD10CM | active | 2023-12 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.78 | Veteran Status Diagnoses | active | 2024-06 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.79 | Social Connection Diagnoses SNOMED CT | active | 2024-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.8 | Social Determinants of Health General Interventions CPT | active | 2024-06 | hl7 | cpt | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.80 | Social Connection Diagnoses ICD10CM | active | 2023-07 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.81 | Social Connection Diagnoses | active | 2024-06 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.82 | Intimate Partner Violence Diagnoses SNOMED CT | active | 2024-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.83 | Intimate Partner Violence Diagnoses ICD10CM | active | 2024-07 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.84 | Intimate Partner Violence Diagnoses | active | 2024-06 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.85 | Stress Goals SNOMED CT | active | 2023-07 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.88 | Social Connection Goals SNOMED CT | active | 2024-12 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.9 | Food Insecurity Interventions HCPCS | active | 2024-06 | hl7 | cms | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.93 | Social Connection Interventions SNOMED CT | active | 2024-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.96 | Intimate Partner Violence Interventions SNOMED CT | active | 2024-12 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1247.99 | Intimate Partner Violence Goals SNOMED CT | active | 2024-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.119 | Opioid Antagonist | active | 2025-02 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.12 | High Risk Diagnosis for AKI | active | 2024-01 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.120 | Opioids | active | 2025-02 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.124 | Immune Modulators | active | 2023-09 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.130 | Suicide Attempt | active | 2023-04 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.134 | Central Nervous System Depressants | active | 2025-02 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.138 | COVID19 | active | 2024-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.139 | COVID 19 | active | 2022-04 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.14 | Hemolytic Uremic Syndrome (HUS) | active | 2023-02 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.140 | COVID 19 | active | 2022-05 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.162 | Obesity | active | 2025-02 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.163 | Antidepressants | active | 2024-01 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.164 | Antihypertensives | active | 2024-01 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.165 | Delirium | active | 2024-01 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.166 | Dementia | active | 2024-01 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.167 | Psychosis | active | 2024-02 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.168 | Delirium or Dementia and Other Psychoses | active | 2022-10 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.169 | Depression | active | 2022-10 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.170 | Diuretics | active | 2024-01 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.171 | Epilepsy | active | 2025-02 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.172 | Neurologic Movement Disorders | active | 2024-01 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.173 | Neurologic Disorders, Other | active | 2024-01 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.174 | Neurologic Movement and Related Disorders | active | 2022-10 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.175 | Peripheral Neuropathy | active | 2022-10 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.176 | Stroke | active | 2024-01 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.177 | Abnormal Weight Loss and Malnutrition | active | 2022-10 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.181 | Tracheostomy Procedures | active | 2022-07 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.187 | Routes of Administration for Opioid Antagonists | active | 2023-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.19 | High Risk Procedures for AKI | active | 2023-02 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.197 | Hospital Based Dialysis Services | active | 2024-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.198 | Hospital Based Dialysis Services | active | 2023-02 | hl7 | cms | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.199 | Hospital Based Dialysis Services | active | 2023-02 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.200 | Nephrectomy | active | 2024-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.201 | Thrombotic Thrombocytopenic Purpura | active | 2023-02 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.204 | VTE Prophylaxis | active | 2024-06 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.206 | General and Neuraxial Anesthesia | active | 2023-04 | hl7 | cms | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.207 | General and Neuraxial Anesthesia | active | 2024-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.208 | General and Neuraxial Anesthesia | active | 2023-04 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.209 | Non Invasive Oxygen Therapy by Nasal Cannula or Mask | active | 2024-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.21 | Creatinine Mass Per Volume | active | 2022-04 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.210 | Continuous and Bilevel Positive Airway Pressure | active | 2023-05 | hl7 | cms | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.211 | Continuous and Bilevel Positive Airway Pressure | active | 2024-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.213 | Non Invasive Oxygen Therapy | active | 2023-05 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.214 | Non Invasive Oxygen Therapy Devices | active | 2024-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.216 | Procedural Hospital Locations | active | 2023-05 | hl7 | cdc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.217 | ASA physical status class | active | 2023-05 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.218 | Blood urea nitrogen lab test | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.219 | Hemoglobin lab test | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.22 | Anticoagulants for All Indications | active | 2022-06 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.220 | Smoking status | active | 2024-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.221 | Albumin lab test | active | 2023-05 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.222 | Leukocyte count lab test | active | 2024-01 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.223 | Bilirubin lab test | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.224 | Aspartate transaminase lab test | active | 2023-05 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.226 | Cardiac Arrest | active | 2024-01 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.230 | PO Antibacterials | active | 2023-09 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.231 | Injectable Antifungals | active | 2023-09 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.24 | Malignant Bone Disease | active | 2022-10 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.242 | Heart and Lung Transplants | active | 2024-01 | hl7 | cms | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.243 | Heart and Lung Transplants | active | 2024-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.245 | Lung Resections and Excisions | active | 2024-01 | hl7 | cms | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.246 | Lung Resections and Excisions | active | 2024-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.247 | Chest Wall Procedures | active | 2024-01 | hl7 | cms | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.248 | Chest Wall Procedures | active | 2024-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.249 | Maxillary Procedures | active | 2024-01 | hl7 | cms | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.250 | Maxillary Procedures | active | 2024-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.251 | Head, Neck, and Thoracic Surgeries with High Risk Airway Compromise | active | 2024-01 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.252 | Anesthesia Requiring Monitored Care | active | 2024-01 | hl7 | cms | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.253 | Anesthesia Requiring Monitored Care | active | 2024-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.255 | Anesthesia Requiring Monitored Care | active | 2024-01 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.256 | Osteoporosis | active | 2025-02 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.260 | Rivaroxaban Anticoagulant | active | 2024-06 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.262 | Fondaparinux Anticoagulant | active | 2024-06 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.263 | Dalteparin Anticoagulant | active | 2024-06 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.264 | Heparin | active | 2024-01 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.268 | Enoxaparin Anticoagulant | active | 2024-06 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.271 | Undetectable Lab Result Value | active | 2025-03 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.272 | Undetectable Lab Result Value | active | 2024-10 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.274 | Dietary Recommendations | active | 2025-01 | hl7 | cpt | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.275 | Bariatric Procedures | active | 2025-03 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.276 | Telemedicine Services | active | 2025-01 | hl7 | cpt | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.277 | Prostate Cancer Treatment | active | 2025-02 | hl7 | cms | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.28 | Traumatic Avulsion of Kidney | active | 2022-04 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.29 | Rapidly Progressive Nephritic Syndrome | active | 2023-02 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.301 | LDL Cholesterol | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.33 | Obstetrics and VTE Obstetrics | active | 2022-04 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.34 | Glucose Lab Test Mass Per Volume | active | 2023-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.349 | Tuberculosis for Urology Care | active | 2025-03 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.350 | Tuberculosis for Urology Care | active | 2025-03 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.351 | Tuberculosis for Urology Care | active | 2025-03 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.352 | Androgen Deprivation Therapy for Urology Care | active | 2025-03 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.353 | Bacillus Calmette Guerin for Urology Care | active | 2025-03 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.354 | Bladder Cancer for Urology Care | active | 2025-03 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.355 | Chemotherapy Agents for Advanced Cancer | active | 2025-03 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.356 | Cystectomy for Urology Care | active | 2025-03 | hl7 | cpt | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.357 | Cystectomy for Urology Care | active | 2025-03 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.358 | Cystectomy for Urology Care | active | 2025-03 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.359 | DEXA Bone Density for Urology Care | active | 2025-03 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.360 | Hospital Services for Urology Care | active | 2025-03 | hl7 | cpt | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.361 | Immunocompromised Conditions | active | 2025-03 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.362 | Immunocompromised Conditions | active | 2025-03 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.363 | Immunocompromised Conditions | active | 2025-03 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.364 | Immunosuppressive Drugs for Urology Care | active | 2025-03 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.365 | Mixed Histology Urothelial Cell Carcinoma for Urology Care | active | 2025-03 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.366 | Morbid Obesity | active | 2025-03 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.367 | Morbid Obesity | active | 2025-03 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.368 | Morbid Obesity | active | 2025-03 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.369 | Unavailability of Bacillus Calmette Guerin for Urology Care | active | 2025-03 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.370 | Urinary Retention | active | 2025-03 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.371 | Urinary Retention | active | 2025-03 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.372 | Urinary Retention | active | 2025-03 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.374 | Face to Face Interaction | active | 2025-03 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.375 | Face to Face Interaction | active | 2025-03 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.376 | HIV Viral Load Tests | active | 2025-03 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.377 | HIV Viral Load Tests | active | 2025-03 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.389 | Syphilis Tests | active | 2025-04 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.4 | Nephrectomy | active | 2023-02 | hl7 | cms | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.8 | Large Body Surface Area (BSA) Burns | active | 2022-04 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1250.2 | Psychological Neuropsychological or Neurobehavioral Testing | active | 2023-11 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1250.3 | Psychological or Neuropsychological Testing | active | 2023-11 | hl7 | cpt | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1251.10 | Tricuspid Valve Regurgitation | active | 2023-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1251.2 | Valvular Heart Disease | active | 2022-05 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1258.1 | Gonorrhea Screening | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1258.2 | Abnormal Weight Loss | active | 2024-10 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1259.2 | Prescribable brand and generic non insulin drugs for hyperglycemia in Type 2 Diabetes | active | 2023-02 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1259.3 | Prescribable brand and generic insulins and analogues | active | 2023-02 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1259.4 | eGFR Using 2021 Race Free Formulas | active | 2023-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1259.5 | Fructosamine in Serum or Plasma | active | 2023-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1259.6 | Glucose tests in venous blood, capillary blood, serum/plasma for Diabetes | active | 2023-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1259.7 | Creatinine in serum/plasma | active | 2023-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1259.9 | IgE Agonists, prescribable | active | 2023-08 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.10 | Estrogen Receptor Testing for Orserdu | active | 2023-08 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.100 | MMR Proficient | active | 2024-01 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.101 | Systemic Cancer Directed Therapy | active | 2024-02 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.102 | Face To Face Interaction | active | 2024-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.104 | Erdafitinib | active | 2024-02 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.107 | Chemotherapy Encounter | active | 2024-02 | hl7 | cpt | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.108 | Urothelial Cancers ICD9 | active | 2024-02 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.109 | Urothelial Cancer ICD10 | active | 2024-02 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.110 | Urothelial Cancers | active | 2024-02 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.111 | Prior Therapies for Erdafitinib | active | 2024-02 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.112 | Urothelial Cancer Histologies | active | 2024-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.113 | Malignant Tumor Behavior | active | 2024-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.114 | Localized Bladder Cancer Stage SNOMED | active | 2024-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.116 | Localized Bladder Cancer Staging | active | 2024-02 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.117 | Advanced Bladder Cancer Stage | active | 2024-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.118 | Localized Bladder Cancer T Stage | active | 2024-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.119 | Localized Bladder Cancer T Stage | active | 2024-02 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.120 | Localized Bladder Cancer N Stage | active | 2024-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.121 | Localized Bladder Cancer M Stage | active | 2024-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.122 | Advanced Bladder Cancer M Stage | active | 2024-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.124 | Locoregional Urothelial Cancer ICD9 | active | 2024-02 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.125 | Locoregional Urothelial Cancer ICD10 | active | 2024-02 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.126 | Locoregional Urothelial Cancer SNOMED | active | 2024-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.127 | Locoregional Urothelial Cancer | active | 2024-02 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.128 | FGFR3 Gene | active | 2024-02 | hl7 | ncit | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.129 | FGFR3 Gene Interpretation Positive SNOMED | active | 2024-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.130 | FGFR3 Gene Interpretation Positive LOINC | active | 2024-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.131 | FGFR3 Gene Interpretation Positive NCI | active | 2024-02 | hl7 | ncit | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.133 | FGFR3 Gene Interpretation Positive | active | 2024-02 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.134 | FGFR3 Gene Interpretation Negative SNOMED | active | 2024-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.135 | FGFR3 Gene Interpretation Negative NCI | active | 2024-02 | hl7 | ncit | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.137 | FGFR3 Gene Interpretation Negative | active | 2024-02 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.138 | FGFR3 Molecular Variants | active | 2024-02 | hl7 | ncit | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.139 | Tumor Behavior | active | 2024-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.140 | Physcological Support for Cancer | active | 2024-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.141 | Referral For Pain From Cancer | active | 2024-04 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.142 | Cancer Pain Education | active | 2024-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.143 | Telehealth Encounters | active | 2024-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.144 | Pain Assessment Score | active | 2024-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.146 | Telehealth Encounters SNOMEDCT | active | 2024-03 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.147 | Telehealth Encounters CPT | active | 2024-03 | hl7 | cpt |
FHIR